The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 21, 2021

Filed:

Mar. 03, 2021
Applicant:

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Daniel G. Anderson, Framingham, MA (US);

Robert Alexander Wesselhoeft, Boston, MA (US);

Piotr S. Kowalski, Allston, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/79 (2006.01); C07H 21/04 (2006.01); C12N 15/85 (2006.01); C07K 16/28 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); C07K 16/2803 (2013.01); C12N 15/11 (2013.01); C07K 2317/31 (2013.01); C12N 2015/859 (2013.01); C12N 2015/8518 (2013.01); C12N 2800/107 (2013.01); C12N 2800/202 (2013.01); C12N 2800/70 (2013.01); C12N 2840/203 (2013.01); C12N 2840/55 (2013.01); C12N 2840/60 (2013.01); C12N 2999/007 (2013.01);
Abstract

Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5' homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f.) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.


Find Patent Forward Citations

Loading…